

Faculty Disclosures and Resolution of Conflict of Interest

Disclosure Policy

Baptist Health has a process in place to ensure balance, independence, objectivity and scientific rigor in CME programming. Through this process Baptist Health identifies and, when applicable, resolves conflicts of interest of all individuals in a position to control or influence CME content, including faculty, conference directors, planners, content reviewers, CME Committee members and the CME Department staff. The CME Department is responsible for content review and, when necessary, makes modifications to resolve conflicts of interest so final presentations are fair and unbiased. These efforts are intended to affirm that the educational content is not controlled or influenced – directly or indirectly – by a commercial interest. As defined by ACCME, a commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Individuals participating in this CME activity are responsible for identifying references to off-label or unapproved product usage in their discussions and recommendations.

Non-faculty Contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

Copyright

Baptist Health is **not** responsible for any image/illustration content prepared by faculty members for their presentations.

Disclosures for individuals in a position to control or influence content are provided below:

Christie Ballantyne, M.D., has disclosed that he receives grant/research support from Abbott Diagnostic, Amarin, Amgen, Esperion, Ionis, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, National Institutes of Health, American Heart Association and American Diabetes Association; also, Dr. Ballantyne serves as a consultant to Abbott Diagnostic, Amarin, Amgen, AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Eli Lilly, Esperion, Ionis, Matinas BioPharma, Inc., Merck, Novartis Pharmaceuticals, Novo Nordisk, Pfizer Pharmaceuticals, Regeneron, Roche Diagnostic and Sanofi-Synthelabo. Dr. Ballantyne has disclosed that his presentations **will** include discussion of off-label or unapproved usage.

Faculty Disclosures and Resolution of Conflict of Interest

Michael Blaha, M.D., has disclosed that he receives grant/research support from Amgen and Aetna, and that he is a member of the advisory board for Amgen, Akcea Therapeutics and Sanofi/Regeneron. Dr. Blaha has indicated that his presentation **will not** include discussion of off-label or unapproved usage.

Ricardo Cury, M.D., has disclosed that he receives grant/research support from GE Healthcare. Dr. Cury has indicated that his presentation **will not** include discussion of off-label or unapproved usage.

Theodore Feldman, M.D., has disclosed that he is a member of the speaker's bureau for Boehringer Ingelheim Pharmaceuticals, Novartis Pharmaceuticals and Regeneron/Sanofi. Dr. Feldman has indicated that his presentation **will not** include discussion of off-label or unapproved usage.

Francisco Javier Jimenez-Carcamo, M.D., has disclosed that he is a member of the speaker's bureaus for Novartis Pharmaceuticals, United Therapeutics, Bayer and Actelion Pharmaceuticals, and that he is a member of the Advisory Board for United Therapeutics and Actelion Pharmaceuticals. Dr. Jimenez-Carcamo has indicated that his presentation **will not** include discussion of off-label or unapproved usage.

Barry Katzen, M.D., has disclosed that he serves as a consultant to Boston Scientific, Bard Medical, Philips Medical and W.L. Gore. Dr. Katzen has indicated that his presentation **will not** include discussion of off-label or unapproved usage.

David Wolinsky, M.D., has disclosed that he is a member of the speaker's bureau for and serves as a consultant to Astellas Pharmaceuticals, and that he is on the Board of Directors for the American Society of Nuclear Cardiology. Dr. Wolinsky has indicated that his presentation **will not** include discussion of off-label or unapproved usage.

Nothing to Disclose

The following faculty members indicated that neither they nor their spouses/partners have relevant financial relationships with commercial interest companies, and they **will not** include off-label or unapproved product usage in their presentations or discussions:

Arthur Agatston, M.D.

Roger Blumenthal, M.D.

Robert Fishel, M.D.

Martha Gulati, M.D.

Michael Hernandez, M.D.

Amishi Jha, Ph.D.

Ashok Mittal, M.D.

Khurram Nasir, M.D.

Michael Ozner, M.D.

Ramon Quesada, M.D.